|
|
News Breaks | | | | December 17, 2012 | | 16:38 EDT |  | SOMX | Somaxon announces Paladin Labs receives NDS for Silenor in Canada
Somaxon Pharmaceuticals announced that its licensee Paladin Labs has received approval from Health Canada of Paladin's New Drug Submission, or NDS, for Silenor for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings. "We are pleased that Health Canada has approved Silenor and commend our colleagues at Paladin for their efforts to bring this important insomnia treatment to the Canadian market. We look forward to Paladin's launch of Silenor, which is expected to occur in the middle of 2013," said Somaxon CEO Richard Pascoe. | |
|
News For SOMX From The Last 14 Days Check below for free stories on SOMX the last two weeks. |
|
|
| There are no results for SOMX |
|
|
|
|
|
|
